Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Fisher

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Journal of the Neurological Sciences|March 19, 2010
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosisErnst-Wilhelm Radue, William H Stuart, Peter A Calabresi, et al.
The Journal of Allergy and Clinical Immunology|April 7, 2007
Prenatal versus postnatal sensitization to environmental allergens in a high-risk birth cohortJulie Rowe, Merci Kusel, Barbara J Holt, et al.
Brain Communications|September 24, 2021
Abnormalities in normal-appearing white matter from which multiple sclerosis lesions ariseColm Elliott, Parya Momayyezsiahkal, Douglas L Arnold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 7, 2017
Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosisJeffrey A Cohen, Peter B Imrey, Sarah M Planchon, et al.
Neurology|September 4, 2016
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MSDouglas L Arnold, Elizabeth Fisher, Vesna V Brinar, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialAlasdair J Coles, Cary L Twyman, Douglas L Arnold, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialJeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
Nature Medicine|August 20, 2025
AI-driven reclassification of multiple sclerosis progressionHabib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Neurology|April 22, 2024
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple SclerosisRobert J Fox, Bruce A C Cree, Jérôme de Sèze, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Journal of the Neurological Sciences|March 19, 2010
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosisErnst-Wilhelm Radue, William H Stuart, Peter A Calabresi, et al.
The Journal of Allergy and Clinical Immunology|April 7, 2007
Prenatal versus postnatal sensitization to environmental allergens in a high-risk birth cohortJulie Rowe, Merci Kusel, Barbara J Holt, et al.
Brain Communications|September 24, 2021
Abnormalities in normal-appearing white matter from which multiple sclerosis lesions ariseColm Elliott, Parya Momayyezsiahkal, Douglas L Arnold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 7, 2017
Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosisJeffrey A Cohen, Peter B Imrey, Sarah M Planchon, et al.
Neurology|September 4, 2016
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MSDouglas L Arnold, Elizabeth Fisher, Vesna V Brinar, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialAlasdair J Coles, Cary L Twyman, Douglas L Arnold, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialJeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
Nature Medicine|August 20, 2025
AI-driven reclassification of multiple sclerosis progressionHabib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Neurology|April 22, 2024
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple SclerosisRobert J Fox, Bruce A C Cree, Jérôme de Sèze, et al.
Pageof 10